Our group is interested in advancing clinical research – especially in type 1 diabetes, but also in the context of other immune-mediated diseases.
We focus on development and utilization of rigorous analytical methods to identify immune features associated with clinical outcomes, including progression of disease and response to therapy. We also seek to implement cutting-edge clinical trial designs, including use of short-term interventions with mechanistic outcomes and novel considerations of trial outcome measures.
With Drs. Lord and Smithmyer, Dr. Speake oversees BRI’s biorepositories. Her group collaborates with other academic researchers worldwide and facilitates collaborations with biotech and pharma companies. She also oversees BRI’s Clinical Core Laboratory, which is responsible for sample processing and storage for the hundreds of thousands of samples currently stored in the BRI biorepository.
Cate Speake, PhD
T1D Risk Screening Event
Join us at BRI on Saturday, March 22 between 9 a.m. and 1 p.m. for our T1D Risk Screening Event. Offered through the TrialNet Pathway to Prevention Study, risk screening uses a simple blood test that can detect your risk of T1D years before symptoms appear.
Lab Members
Christine Bender, PhD
Linda Dement
Bradford Dimos, PhD
Rachel Hartley, PMP
Pamela Miranda
Thien-Son Nguyen, BS
Sarah Robinson
Jessica Sarratt
Megan Smithmyer, PhD
Cameron Willman
Research Projects
Rigor and Reproducibility in T1D Biomarker Research
The Sound Life Project
Understanding Progression of T1D
Featured Publications
-
Oct 2022
IL-6-targeted therapies directed to cytokine or receptor blockade drive distinct alterations in T cell function.
JCI InsightSpeake C, Habib T, Lambert K, Hundhausen C, Lord S, Dufort MJ, Skinner SO, Hu A, Kinsman M, Jones BE, Maerz MD, Tatum M, Hocking AM, Nepom GT, Greenbaum CJ, Buckner JH -
Apr 2020
Autoantibody Reversion: Changing Risk Categories in Multiple-Autoantibody-Positive Individuals.
Diabetes CareSo M, O'Rourke C, Bahnson HT, Greenbaum CJ, Speake C -
Dec 2019
A composite immune signature parallels disease progression across T1D subjects.
JCI InsightSpeake C, Skinner SO, Berel D, Whalen E, Dufort MJ, Young WC, Odegard JM, Pesenacker AM, Gorus FK, James EA, Levings MK, Linsley PS, Akirav EM, Pugliese A, Hessner MJ, Nepom GT, Gottardo R, Long SA -
Mar 2023
SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity.
Nat CommunJaycox JR, Lucas C, Yildirim I, Dai Y, Wang EY, Monteiro V, Lord S, Carlin J, Kita M, Buckner JH, Ma S, Campbell M, Ko A, Omer S, Lucas CL, Speake C, Iwasaki A, Ring AM -
Jul 2022
Evaluating the Immunopathogenesis of Diabetes After Acute Pancreatitis in the Diabetes RElated to Acute Pancreatitis and Its Mechanisms Study: From the Type 1 Diabetes in Acute Pancreatitis Consortium.
PancreasCasu A, Grippo PJ, Wasserfall C, Sun Z, Linsley PS, Hamerman JA, Fife BT, Lacy-Hulbert A, Toledo FGS, Hart PA, Papachristou GI, Bellin MD, Yadav D, Laughlin MR, Goodarzi MO, Speake C, Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC).
Innovation Grant Yields Exciting Advances and Additional Funding
Catching Autoimmune Diseases Before They Start
